海南海药(000566.SZ)：控股子公司富马酸伏诺拉生原料药取得上市申请批准通知书

格隆汇2025-05-07

格隆汇5月7日丨海南海药(000566.SZ)公布，公司控股子公司重庆天地药业有限责任公司近日获得国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》(通知书编号：2025YS00357)。富马酸伏诺拉生是一款钾离子竞争性酸阻滞剂(P-CAB)，与传统的质子泵抑制剂(PPI)相比，伏诺拉生具有更快的起效速度、更长的作用时间和更强的抑制胃酸分泌效果。目前富马酸伏诺拉生国内适应症...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533982611?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-07 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533982611","market":"us","top_or_hot":-1,"title":"海南海药(000566.SZ)：控股子公司富马酸伏诺拉生原料药取得上市申请批准通知书","media":"格隆汇","content":"<div>\n<p>格隆汇5月7日丨海南海药(000566.SZ)公布，公司控股子公司重庆天地药业有限责任公司近日获得国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》(通知书编号：2025YS00357)。富马酸伏诺拉生是一款钾离子竞争性酸阻滞剂(P-CAB)，与传统的质子泵抑制剂(PPI)相比，伏诺拉生具有更快的起效速度、更长的作用时间和更强的抑制胃酸分泌效果。目前富马酸伏诺拉生国内适应症...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/05/07200950204806.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海南海药(000566.SZ)：控股子公司富马酸伏诺拉生原料药取得上市申请批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海南海药(000566.SZ)：控股子公司富马酸伏诺拉生原料药取得上市申请批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 20:09 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.jrj.com.cn/2025/05/07200950204806.shtml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇5月7日丨海南海药(000566.SZ)公布，公司控股子公司重庆天地药业有限责任公司近日获得国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》(通知书编号：2025YS00357)。富马酸伏诺拉生是一款钾离子竞争性酸阻滞剂(P-CAB)，与传统的质子泵抑制剂(PPI)相比，伏诺拉生具有更快的起效速度、更长的作用时间和更强的抑制胃酸分泌效果。目前富马酸伏诺拉生国内适应症...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/05/07200950204806.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://finance.jrj.com.cn/2025/05/07200950204806.shtml","article_id":"2533982611","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533982611","pubTimestamp":1746619747,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"格隆汇5月7日丨海南海药公布，公司控股子公司重庆天地药业有限责任公司近日获得国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》。富马酸伏诺拉生是首个应用于中国RE患者的P-CAB，以其“首剂全效”+“持久抑酸”的临床特点，从而达到RE患者更高的黏膜愈合率，有利于提高患者依从性，成为中国RE患者治疗临床用药提供新选择。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0060":"抗癌","000566":"海南海药","BK0146":"智慧医疗","BK0239":"医药制造","BK0188":"融资融券","BK0070":"员工持股"},"translate_title":"Hainan Haiyao (000566. SZ): The holding subsidiary Vonolason Fumarate API obtained the marketing application approval notice","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000566":1},"content_text":"格隆汇5月7日丨海南海药(000566.SZ)公布，公司控股子公司重庆天地药业有限责任公司近日获得国家药品监督管理局核准签发的富马酸伏诺拉生《化学原料药上市申请批准通知书》(通知书编号：2025YS00357)。富马酸伏诺拉生是一款钾离子竞争性酸阻滞剂(P-CAB)，与传统的质子泵抑制剂(PPI)相比，伏诺拉生具有更快的起效速度、更长的作用时间和更强的抑制胃酸分泌效果。目前富马酸伏诺拉生国内适应症为：反流性食管炎(RE)，与适当的抗生素联用以根除幽门螺杆菌。富马酸伏诺拉生是首个应用于中国RE患者的P-CAB，以其“首剂全效”+“持久抑酸”的临床特点，从而达到RE患者更高的黏膜愈合率，有利于提高患者依从性，成为中国RE患者治疗临床用药提供新选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533982611","isCrawlerRequest":true}